Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
89.05 CHF | +0.20% | +1.93% | +4.93% |
Apr. 30 | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
Apr. 30 | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.93% | 198B | |
+34.00% | 704B | |
+27.29% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.06% | 234B | |
-9.78% | 194B | |
-4.89% | 147B | |
-11.01% | 145B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says